The FDA has granted Vistagen fast track designation for PH10, a nasal spray for the treatment of major depressive disorder, according to a company press release.
Vistagen is a late-stage biopharmaceutical company aiming to transform treatment for individuals with depression, anxiety and other central nervous symptoms disorders.
The FDA’s fast track program focuses on the development and review of new drugs for the treatment of life-threatening conditions and bringing new medicines to patients sooner.
“Vistagen is laser focused on bringing an innovative treatment option to individuals